On the public citation graph
Design and application of oncolytic viruses for cancer immunotherapy
0 signed · 250 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1002/ijc.32325openalex-snapshot
Oncolytic virotherapy enhances the efficacy of a cancer vaccine by modulating the tumor microenvironment
inferredcites →https://doi.org/10.1002/jcp.27425openalex-snapshot
Tumor microenvironment: Interactions and therapy
inferredcites →https://doi.org/10.1002/mabi.201700187openalex-snapshot
Solid Tumor Immunotherapy with T Cell Engager‐Armed Oncolytic Viruses
inferredcites →https://doi.org/10.1007/s00262-013-1507-6openalex-snapshot
Enhanced therapeutic anti-tumor immunity induced by co-administration of 5-fluorouracil and adenovirus expressing CD40 ligand
inferredcites →https://doi.org/10.1007/s00262-014-1523-1openalex-snapshot
Interleukin 12: still a promising candidate for tumor immunotherapy?
inferredcites →https://doi.org/10.1007/s11523-019-00665-1openalex-snapshot
Immune Checkpoint Inhibitors as Switch or Continuation Maintenance Therapy in Solid Tumors: Rationale and Current State
inferredcites →https://doi.org/10.1007/s40257-016-0238-9openalex-snapshot
Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma
inferredcites →https://doi.org/10.1016/j.ccell.2017.07.006openalex-snapshot
Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade
inferredcites →https://doi.org/10.1016/j.cell.2017.08.027openalex-snapshot
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy
inferredcites →https://doi.org/10.1016/j.cellimm.2017.06.002openalex-snapshot
The combination of NK and CD8+ T cells with CCL20/IL15-armed oncolytic adenoviruses enhances the growth suppression of TERT-positive tumor cells
inferredcites →https://doi.org/10.1016/j.cytogfr.2018.03.006openalex-snapshot
Armed oncolytic viruses: A kick-start for anti-tumor immunity
inferredcites →https://doi.org/10.1016/j.imlet.2014.02.009openalex-snapshot
Genetically engineered Newcastle disease virus expressing interleukin 2 is a potential drug candidate for cancer immunotherapy
inferredcites →https://doi.org/10.1016/j.intimp.2015.07.005openalex-snapshot
Enhanced growth suppression of TERT-positive tumor cells by oncolytic adenovirus armed with CCL20 and CD40L
inferredcites →https://doi.org/10.1016/j.jphs.2016.03.012openalex-snapshot
Recombinant Newcastle disease virus (NDV/Anh-IL-2) expressing human IL-2 as a potential candidate for suppresses growth of hepatoma therapy
inferredcites →https://doi.org/10.1016/j.omto.2016.12.004openalex-snapshot
Oncolytic Adenoviruses Armed with Tumor Necrosis Factor Alpha and Interleukin-2 Enable Successful Adoptive Cell Therapy
inferredcites →https://doi.org/10.1016/j.surg.2016.08.045openalex-snapshot
Oncolytic influenza A virus expressing interleukin-15 decreases tumor growth in vivo
inferredcites →https://doi.org/10.1016/j.virusres.2008.04.020openalex-snapshot
Recombinant Newcastle disease virus expressing human interleukin-2 serves as a potential candidate for tumor therapy
inferredcites →https://doi.org/10.1016/j.virusres.2016.05.002openalex-snapshot
CCL21/IL21-armed oncolytic adenovirus enhances antitumor activity against TERT-positive tumor cells
inferredcites →https://doi.org/10.1016/j.ymthe.2018.06.001openalex-snapshot
Adenovirus Coding for Interleukin-2 and Tumor Necrosis Factor Alpha Replaces Lymphodepleting Chemotherapy in Adoptive T Cell Therapy
inferredcites →https://doi.org/10.1016/j.ymthe.2018.06.008openalex-snapshot
Personalized Cancer Vaccine Platform for Clinically Relevant Oncolytic Enveloped Viruses
inferredcites →https://doi.org/10.1016/s0065-2776(10)05003-0openalex-snapshot
OX40–OX40 Ligand Interaction in T-Cell-Mediated Immunity and Immunopathology
inferredcites →https://doi.org/10.1038/30996openalex-snapshot
Help for cytotoxic-T-cell responses is mediated by CD40 signalling
inferredcites →https://doi.org/10.1038/31002openalex-snapshot
T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions
inferredcites →https://doi.org/10.1038/bjc.2016.42openalex-snapshot
Immunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients
inferredcites →https://doi.org/10.1038/cgt.2011.81openalex-snapshot
Expressing human interleukin-15 from oncolytic vesicular stomatitis virus improves survival in a murine metastatic colon adenocarcinoma model through the enhancement of anti-tumor immunity
inferredcites →https://doi.org/10.1038/cgt.2014.2openalex-snapshot
CD40L gene therapy tilts the myeloid cell profile and promotes infiltration of activated T lymphocytes
inferredcites →https://doi.org/10.1038/cgt.2015.2openalex-snapshot
The addition of recombinant vaccinia HER2/neu to oncolytic vaccinia-GMCSF given into the tumor microenvironment overcomes MDSC-mediated immune escape and systemic anergy
inferredcites →https://doi.org/10.1038/gt.2009.14openalex-snapshot
Genetically engineered Newcastle disease virus for malignant melanoma therapy
inferredcites →https://doi.org/10.1038/gt.2016.80openalex-snapshot
Activation of myeloid and endothelial cells by CD40L gene therapy supports T-cell expansion and migration into the tumor microenvironment
inferredcites →https://doi.org/10.1038/mt.2010.103openalex-snapshot
Identification of Genetically Modified Maraba Virus as an Oncolytic Rhabdovirus
inferredcites →https://doi.org/10.1038/mt.2013.240openalex-snapshot
T-cell Engager-armed Oncolytic Vaccinia Virus Significantly Enhances Antitumor Therapy
inferredcites →https://doi.org/10.1038/mt.2013.249openalex-snapshot
Maraba Virus as a Potent Oncolytic Vaccine Vector
inferredcites →https://doi.org/10.1038/mt.2014.160openalex-snapshot
CTLA-4 and PD-L1 Checkpoint Blockade Enhances Oncolytic Measles Virus Therapy
inferredcites →https://doi.org/10.1038/mt.2016.137openalex-snapshot
Adenoviral Delivery of Tumor Necrosis Factor-α and Interleukin-2 Enables Successful Adoptive Cell Therapy of Immunosuppressive Melanoma
inferredcites →https://doi.org/10.1038/nature13954openalex-snapshot
PD-1 blockade induces responses by inhibiting adaptive immune resistance
inferredcites →https://doi.org/10.1038/ncomms14754openalex-snapshot
Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy
inferredcites →https://doi.org/10.1038/nm.3089openalex-snapshot
Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer
inferredcites →https://doi.org/10.1038/nrd4663openalex-snapshot
Oncolytic viruses: a new class of immunotherapy drugs
inferredcites →https://doi.org/10.1038/nri.2017.49openalex-snapshot
Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy
inferredcites →https://doi.org/10.1038/s41388-019-0870-yopenalex-snapshot
Oncolytic herpes simplex virus immunotherapy for brain tumors: current pitfalls and emerging strategies to overcome therapeutic resistance
inferredcites →https://doi.org/10.1038/s41573-019-0029-0openalex-snapshot
Optimizing oncolytic virotherapy in cancer treatment
inferredcites →https://doi.org/10.1038/s41590-019-0441-yopenalex-snapshot
PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance
inferredcites →https://doi.org/10.1038/s41598-017-15992-4openalex-snapshot
Maraba virus-vectored cancer vaccines represent a safe and novel therapeutic option for cats
inferredcites →https://doi.org/10.1038/sj.cgt.7700781openalex-snapshot
Bypassing tumor-associated immune suppression with recombinant adenovirus constructs expressing membrane bound or secreted GITR-L
inferredcites →https://doi.org/10.1038/sj.cgt.7700900openalex-snapshot
Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers
inferredcites →https://doi.org/10.1038/sj.gt.3301885openalex-snapshot
ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties
inferredcites →https://doi.org/10.1038/sj.gt.3303026openalex-snapshot
Recombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy
inferredcites →https://doi.org/10.1039/c7sc04853jopenalex-snapshot
Dual-targeting biomimetic delivery for anti-glioma activity via remodeling the tumor microenvironment and directing macrophage-mediated immunotherapy
inferredcites →https://doi.org/10.1046/j.1365-2265.2003.01915.xopenalex-snapshot
Thyroid cancer immuno‐therapy with retroviral and adenoviral vectors expressing granulocyte macrophage colony stimulating factor and interleukin‐12 in a rat model
inferredcites →https://doi.org/10.1056/nejmoa1716435openalex-snapshot
Recurrent Glioblastoma Treated with Recombinant Poliovirus
inferredcites →https://doi.org/10.1080/2162402x.2015.1105429openalex-snapshot
Oncolytic adenoviruses coated with MHC-I tumor epitopes increase the antitumor immunity and efficacy against melanoma
inferredcites →https://doi.org/10.1080/2162402x.2017.1395997openalex-snapshot
Intra-tumoral delivery of CXCL11 via a vaccinia virus, but not by modified T cells, enhances the efficacy of adoptive T cell therapy and vaccines
inferredcites →https://doi.org/10.1080/2162402x.2017.1412902openalex-snapshot
TNFa and IL-2 armed adenoviruses enable complete responses by anti-PD-1 checkpoint blockade
inferredcites →https://doi.org/10.1080/2162402x.2018.1445459openalex-snapshot
Transforming the prostatic tumor microenvironment with oncolytic virotherapy
inferredcites →https://doi.org/10.1080/2162402x.2018.1457596openalex-snapshot
Oncolytic vaccines increase the response to PD-L1 blockade in immunogenic and poorly immunogenic tumors
inferredcites →https://doi.org/10.1080/2162402x.2018.1490856openalex-snapshot
CD40L coding oncolytic adenovirus allows long-term survival of humanized mice receiving dendritic cell therapy
inferredcites →https://doi.org/10.1080/2162402x.2018.1512329openalex-snapshot
Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials
inferredcites →https://doi.org/10.1080/2162402x.2019.1615817openalex-snapshot
Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE)
inferredcites →https://doi.org/10.1089/10430340150218396openalex-snapshot
Cytokine Gene Transfer Enhances Herpes Oncolytic Therapy in Murine Squamous Cell Carcinoma
inferredcites →https://doi.org/10.1089/hum.2005.16.765openalex-snapshot
Oncolytic HSV Exerts Direct Antiangiogenic Activity in Ovarian Carcinoma
inferredcites →https://doi.org/10.1089/hum.2009.143openalex-snapshot
Interference of CD40L-Mediated Tumor Immunotherapy by Oncolytic Vesicular Stomatitis Virus
inferredcites →https://doi.org/10.1089/hum.2012.205openalex-snapshot
Granulocyte-Macrophage Colony-Stimulating Factor-Armed Oncolytic Measles Virus Is an Effective Therapeutic Cancer Vaccine
inferredcites →https://doi.org/10.1089/humc.2016.031openalex-snapshot
Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma
inferredcites →https://doi.org/10.1089/jir.2014.0149openalex-snapshot
Dual Role of GM-CSF as a Pro-Inflammatory and a Regulatory Cytokine: Implications for Immune Therapy
inferredcites →https://doi.org/10.1093/neuonc/nov173openalex-snapshot
Combination viroimmunotherapy with checkpoint inhibition to treat glioma, based on location-specific tumor profiling
inferredcites →https://doi.org/10.1097/cji.0b013e31829d8a1bopenalex-snapshot
Treatment Efficacy and Immune Stimulation by AdCD40L Gene Therapy of Spontaneous Canine Malignant Melanoma
inferredcites →https://doi.org/10.1128/jvi.06998-11openalex-snapshot
Preclinical Evaluation of a Genetically Engineered Herpes Simplex Virus Expressing Interleukin-12
inferredcites →https://doi.org/10.1136/esmoopen-2019-000510openalex-snapshot
New emerging targets in cancer immunotherapy: the role of Cluster of Differentiation 40 (CD40/TNFR5)
inferredcites →https://doi.org/10.1158/0008-5472.can-11-2975openalex-snapshot
Immune Response Is an Important Aspect of the Antitumor Effect Produced by a CD40L-Encoding Oncolytic Adenovirus
inferredcites →https://doi.org/10.1158/0008-5472.can-11-3001openalex-snapshot
Oncolytic Immunotherapy of Advanced Solid Tumors with a CD40L-Expressing Replicating Adenovirus: Assessment of Safety and Immunologic Responses in Patients
inferredcites →https://doi.org/10.1158/0008-5472.can-12-2687openalex-snapshot
Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans
inferredcites →https://doi.org/10.1158/0008-5472.can-14-0697openalex-snapshot
Armed Oncolytic Virus Enhances Immune Functions of Chimeric Antigen Receptor–Modified T Cells in Solid Tumors
inferredcites →https://doi.org/10.1158/0008-5472.can-15-3308openalex-snapshot
Amplification of Oncolytic Vaccinia Virus Widespread Tumor Cell Killing by Sunitinib through Multiple Mechanisms
inferredcites →https://doi.org/10.1158/0008-5472.can-16-2165openalex-snapshot
Immune Checkpoint Blockade, Immunogenic Chemotherapy or IFN-α Blockade Boost the Local and Abscopal Effects of Oncolytic Virotherapy
inferredcites →https://doi.org/10.1158/0008-5472.can-17-0468openalex-snapshot
Oncolytic Adenovirus and Tumor-Targeting Immune Modulatory Therapy Improve Autologous Cancer Vaccination
inferredcites →https://doi.org/10.1158/1078-0432.ccr-05-1494openalex-snapshot
Triple Combination of Oncolytic Herpes Simplex Virus-1 Vectors Armed with Interleukin-12, Interleukin-18, or Soluble B7-1 Results in Enhanced Antitumor Efficacy
inferredcites →https://doi.org/10.1158/1078-0432.ccr-05-2038openalex-snapshot
A Phase 1 Clinical Study of Intravenous Administration of PV701, an Oncolytic Virus, Using Two-Step Desensitization
inferredcites →https://doi.org/10.1158/1078-0432.ccr-10-0385openalex-snapshot
AdCD40L Immunogene Therapy for Bladder Carcinoma—The First Phase I/IIa Trial
inferredcites →https://doi.org/10.1158/1078-0432.ccr-14-2009openalex-snapshot
Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy
inferredcites →https://doi.org/10.1158/1078-0432.ccr-17-0285openalex-snapshot
Shaping the Tumor Stroma and Sparking Immune Activation by CD40 and 4-1BB Signaling Induced by an Armed Oncolytic Virus
inferredcites →https://doi.org/10.1158/1078-0432.ccr-18-4022openalex-snapshot
Phase I Trial of an ICAM-1-Targeted Immunotherapeutic-Coxsackievirus A21 (CVA21) as an Oncolytic Agent Against Non Muscle-Invasive Bladder Cancer
inferredcites →https://doi.org/10.1158/1078-0432.ccr-19-0405openalex-snapshot
Localized Treatment with Oncolytic Adenovirus Delta-24-RGDOX Induces Systemic Immunity against Disseminated Subcutaneous and Intracranial Melanomas
inferredcites →https://doi.org/10.1158/1538-7445.am2018-ct072openalex-snapshot
Abstract CT072: First in human (FIH) dose escalation studies of intravenous administration of VSV-IFNβ-NIS (Voyager-V1™) in Stage IV or recurrent endometrial cancer
inferredcites →https://doi.org/10.1158/1538-7445.am2019-1456openalex-snapshot
Abstract 1456: MEDI5395: A recombinant oncolytic virus with oncolytic and immune modulatory properties
inferredcites →https://doi.org/10.1158/2159-8290.cd-15-1545openalex-snapshot
Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade
inferredcites →https://doi.org/10.1158/2326-6066.cir-14-0216openalex-snapshot
Virotherapy with a Semliki Forest Virus–Based Vector Encoding IL12 Synergizes with PD-1/PD-L1 Blockade
inferredcites →https://doi.org/10.1158/2326-6066.cir-17-0102openalex-snapshot
Customized Viral Immunotherapy for HPV-Associated Cancer
inferredcites →https://doi.org/10.1172/jci.insight.99573openalex-snapshot
Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses
inferredcites →https://doi.org/10.1172/jci24624openalex-snapshot
Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma
inferredcites →https://doi.org/10.1182/blood-2015-06-652503openalex-snapshot
Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia
inferredcites →https://doi.org/10.1186/1476-4598-12-103openalex-snapshot
Oncolytic viruses as therapeutic cancer vaccines
inferredcites →https://doi.org/10.1186/1479-5876-11-54openalex-snapshot
The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment
inferredcites →https://doi.org/10.1186/s12967-017-1182-zopenalex-snapshot
Adenovirus-mediated CD40L gene transfer increases Teffector/Tregulatory cell ratio and upregulates death receptors in metastatic melanoma patients
inferredcites →https://doi.org/10.1186/s40425-016-0121-5openalex-snapshot
Phase I study with ONCOS-102 for the treatment of solid tumors – an evaluation of clinical response and exploratory analyses of immune markers
inferredcites →https://doi.org/10.1186/s40425-017-0277-7openalex-snapshot
Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection
inferredcites →https://doi.org/10.1186/s40425-018-0337-7openalex-snapshot
Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case series
inferredcites →https://doi.org/10.1186/s40425-018-0495-7openalex-snapshot
Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics
inferredcites →https://doi.org/10.1186/s40425-019-0510-7openalex-snapshot
A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE)
inferredcites →https://doi.org/10.1186/s40425-019-0623-zopenalex-snapshot
Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma
inferredcites →https://doi.org/10.1200/edbk_156572openalex-snapshot
Basic Overview of Current Immunotherapy Approaches in Cancer
inferredcites →https://doi.org/10.1200/jco.2014.58.3377openalex-snapshot
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
inferredcites →https://doi.org/10.1200/jco.2016.67.1529openalex-snapshot
Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma
inferredcites →https://doi.org/10.1200/jco.2017.73.7379openalex-snapshot
Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma
inferredcites →https://doi.org/10.1245/s10434-016-5286-0openalex-snapshot
Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial
inferredcites →https://doi.org/10.15252/emmm.201707567openalex-snapshot
Oncolytic adenovirus expressing bispecific antibody targets T‐cell cytotoxicity in cancer biopsies
inferredcites →https://doi.org/10.1530/erc-17-0146openalex-snapshot
The role of the tumour microenvironment in immunotherapy
inferredcites →https://doi.org/10.1593/neo.121272openalex-snapshot
Expression of CCL19 from Oncolytic Vaccinia Enhances Immunotherapeutic Potential while Maintaining Oncolytic Activity
inferredcites →https://doi.org/10.2174/1568009617666170222125035openalex-snapshot
Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects
inferredcites →https://doi.org/10.2174/157489213805290556openalex-snapshot
The Use of Cytokines and Chemokines in the Cancer Immunotherapy
inferredcites →https://doi.org/10.2217/imt-2018-0009openalex-snapshot
Oncolytic Herpes Simplex Virus Immunovirotherapy in Combination with Immune Checkpoint Blockade to Treat Glioblastoma
inferredcites →https://doi.org/10.3389/fimmu.2018.00527openalex-snapshot
Contribution to Tumor Angiogenesis From Innate Immune Cells Within the Tumor Microenvironment: Implications for Immunotherapy
inferredcites →https://doi.org/10.3389/fonc.2014.00074openalex-snapshot
Oncolytic Immunotherapy: Dying the Right Way is a Key to Eliciting Potent Antitumor Immunity
inferredcites →https://doi.org/10.3390/cancers10060160openalex-snapshot
A Phase II Study of Pelareorep (REOLYSIN®) in Combination with Gemcitabine for Patients with Advanced Pancreatic Adenocarcinoma
inferredcites →https://doi.org/10.3390/ijms20174320openalex-snapshot
The Janus Face of Tumor Microenvironment Targeted by Immunotherapy
inferredcites →https://doi.org/10.3390/v10090455openalex-snapshot
Modulation of the Tumor Microenvironment by CXCR4 Antagonist-Armed Viral Oncotherapy Enhances the Antitumor Efficacy of Dendritic Cell Vaccines against Neuroblastoma in Syngeneic Mice
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.4652904openalex-extracted
A Dual-Functional Oncolytic Adenovirus Armed with Pd-L1 Inhibitor Potentiates its Antitumor Activity
inferred← citeshttps://doi.org/10.1002/adbi.202200336openalex-snapshot
Natural Oncolysis of Enterovirus 71 in Antitumor Therapy of Colorectal Cancer
inferred← citeshttps://doi.org/10.1002/adma.202519222openalex-snapshot
Innovative Biomaterials Synergize Oncolytic Virus for Elevating Tumor Immunotherapy Potency
inferred← citeshttps://doi.org/10.1002/advs.202207697openalex-snapshot
In Situ Cocktail Nanovaccine for Cancer Immunotherapy
inferred← citeshttps://doi.org/10.1002/cac2.12597openalex-snapshot
Beyond the Gut: The intratumoral microbiome's influence on tumorigenesis and treatment response
inferred← citeshttps://doi.org/10.1002/cai2.101openalex-snapshot
Organoid co‐culture models of the tumor microenvironment promote precision medicine
inferred← citeshttps://doi.org/10.1002/jmv.70220openalex-snapshot
The Novel Oncolytic Herpes Simplex Virus Type‐1 (HSV‐1) Vaccine Strain VC2 Constitutively Expressing GM‐CSF Causes Increased Intratumoral T Cell Infiltration and Inhibition of Tumor Metastasis in the 4T1/Balb/c Mouse Model of Stage Four Breast Cancer
inferred← citeshttps://doi.org/10.1002/mog2.23openalex-snapshot
Oncolytic virotherapy using neural stem cells as a novel treatment option for glioblastoma multiforme
inferred← citeshttps://doi.org/10.1002/smll.202401631openalex-snapshot
Cancer Nanovaccines: Nanomaterials and Clinical Perspectives
inferred← citeshttps://doi.org/10.1002/smtd.202300347openalex-snapshot
Local Drug Delivery Techniques for Triggering Immunogenic Cell Death
inferred← citeshttps://doi.org/10.1007/16833_2023_153openalex-snapshot
Macrophage-Mediated Cancer Immunology in Cutaneous Malignancies
inferred← citeshttps://doi.org/10.1007/978-3-030-65317-0_7openalex-snapshot
Viruses Are Part of the Holobiont’s Fitness and Evolution
inferred← citeshttps://doi.org/10.1007/978-3-031-64532-7_13openalex-snapshot
Oncolytic Viruses and Cell Migration
inferred← citeshttps://doi.org/10.1007/s00018-020-03486-yopenalex-snapshot
Building sophisticated sensors of extracellular cues that enable mammalian cells to work as “doctors” in the body
inferred← citeshttps://doi.org/10.1007/s00210-025-04208-6openalex-snapshot
Combination therapies and novel delivery systems: a new frontier in overcoming TRAIL resistance in gastric cancer
inferred← citeshttps://doi.org/10.1007/s00253-020-10802-wopenalex-snapshot
The limiting factors of oncolytic virus immunotherapy and the approaches to overcome them
inferred← citeshttps://doi.org/10.1007/s00262-024-03708-3openalex-snapshot
The biological roles of CD47 in ovarian cancer progression
inferred← citeshttps://doi.org/10.1007/s13365-024-01209-8openalex-snapshot
A viral attack on brain tumors: the potential of oncolytic virus therapy
inferred← citeshttps://doi.org/10.1007/s40259-025-00743-zopenalex-snapshot
Oncolytic Virotherapy in Solid Tumors: A Current Review
inferred← citeshttps://doi.org/10.1007/s40291-023-00689-4openalex-snapshot
Personalizing Oncolytic Immunovirotherapy Approaches
inferred← citeshttps://doi.org/10.1007/s44337-025-00328-3openalex-snapshot
Exploring the potential of oncolytic viral vectors in targeted cancer therapy: advances, challenges and future directions
inferred← citeshttps://doi.org/10.1016/b978-0-12-821749-8.00011-2openalex-snapshot
Implantable and long-lasting drug delivery systems for cancer treatment
inferred← citeshttps://doi.org/10.1016/b978-0-443-18770-4.00004-4openalex-snapshot
Immunoadjuvants for cancer immunotherapy
inferred← citeshttps://doi.org/10.1016/bs.acr.2026.01.017openalex-snapshot
Oncolytic viruses in cutaneous oncology: Mechanisms, clinical applications, and future directions
inferred← citeshttps://doi.org/10.1016/j.addr.2021.113927openalex-snapshot
Enhancing therapeutic performance of personalized cancer vaccine via delivery vectors
inferred← citeshttps://doi.org/10.1016/j.ajps.2024.100890openalex-snapshot
Design of pH-responsive antimicrobial peptide melittin analog-camptothecin conjugates for tumor therapy
inferred← citeshttps://doi.org/10.1016/j.annonc.2021.08.2153openalex-snapshot
Therapeutic cancer vaccines revamping: technology advancements and pitfalls
inferred← citeshttps://doi.org/10.1016/j.canlet.2022.215661openalex-snapshot
Oncolytic adenovirus-mediated intratumoral expression of TRAIL and CD40L enhances immunotherapy by modulating the tumor microenvironment in immunocompetent mouse models
inferred← citeshttps://doi.org/10.1016/j.canlet.2023.216167openalex-snapshot
Improvement strategy for immune checkpoint blockade: A focus on the combination with immunogenic cell death inducers
inferred← citeshttps://doi.org/10.1016/j.canlet.2023.216456openalex-snapshot
Oncolytic adenovirus as pancreatic cancer-targeted therapy: Where do we go from here?
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2023.103980openalex-snapshot
Nano based-oncolytic viruses for cancer therapy
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2024.104604openalex-snapshot
Synergistic effects of immunotherapy and adjunctive therapies in prostate cancer management
inferred← citeshttps://doi.org/10.1016/j.gendis.2025.101599openalex-snapshot
Recent advances in oncolytic virus combined immunotherapy in tumor treatment
inferred← citeshttps://doi.org/10.1016/j.immuno.2022.100011openalex-snapshot
Improving immunovirotherapies: the intersection of mathematical modelling and experiments
inferred← citeshttps://doi.org/10.1016/j.intimp.2020.106944openalex-snapshot
Therapeutic vaccines for colorectal cancer: The progress and future prospect
inferred← citeshttps://doi.org/10.1016/j.intimp.2022.109071openalex-snapshot
Recent trends in T7 phage application in diagnosis and treatment of various diseases
inferred← citeshttps://doi.org/10.1016/j.intimp.2023.110470openalex-snapshot
Hypoxia effects on oncolytic virotherapy in Cancer: Friend or Foe?
inferred← citeshttps://doi.org/10.1016/j.intimp.2024.111579openalex-snapshot
A dual-functional oncolytic adenovirus ZD55-aPD-L1 scFv armed with PD-L1 inhibitor potentiates its antitumor activity
inferred← citeshttps://doi.org/10.1016/j.intimp.2024.112393openalex-snapshot
A PD-L1 tropism-expanded oncolytic adenovirus enhanced gene delivery efficiency and anti-tumor effects
inferred← citeshttps://doi.org/10.1016/j.isci.2025.114127openalex-snapshot
CCL19-armed recombinant influenza virus inhibited colorectal cancer growth by remodeling tumor microenvironment
inferred← citeshttps://doi.org/10.1016/j.microb.2025.100344openalex-snapshot
CRISPR Cas systems: From bacterial defense mechanisms to revolutionary tools reshaping genetic research and translation therapeutics
inferred← citeshttps://doi.org/10.1016/j.omtm.2021.01.014openalex-snapshot
GAMER-Ad: a novel and rapid method for generating recombinant adenoviruses
inferred← citeshttps://doi.org/10.1016/j.omto.2023.05.002openalex-snapshot
Oncolytic therapy with recombinant vaccinia viruses targeting the interleukin-15 pathway elicits a synergistic response
inferred← citeshttps://doi.org/10.1016/j.omto.2023.100732openalex-snapshot
Oncolytic virotherapy targeting the IL15 pathway
inferred← citeshttps://doi.org/10.1016/j.pharmthera.2021.108103openalex-snapshot
Oncolytic ImmunoViroTherapy: A long history of crosstalk between viruses and immune system for cancer treatment
inferred← citeshttps://doi.org/10.1016/j.pharmthera.2023.108521openalex-snapshot
Potential targeting of the tumor microenvironment to improve cancer virotherapy
inferred← citeshttps://doi.org/10.1016/j.semcancer.2021.05.019openalex-snapshot
Optimal timing of PD-1 blockade in combination with oncolytic virus therapy
inferred← citeshttps://doi.org/10.1016/j.semcancer.2021.06.021openalex-snapshot
Virus-inspired strategies for cancer therapy
inferred← citeshttps://doi.org/10.1016/j.semcancer.2021.10.004openalex-snapshot
Dynamic impact of virome on colitis and colorectal cancer: Immunity, inflammation, prevention and treatment
inferred← citeshttps://doi.org/10.1016/j.semcancer.2025.01.007openalex-snapshot
Study of immunosenescence in the occurrence and immunotherapy of gastrointestinal malignancies
inferred← citeshttps://doi.org/10.1016/j.smim.2020.101430openalex-snapshot
New viral vectors for infectious diseases and cancer
inferred← citeshttps://doi.org/10.1016/j.smim.2023.101750openalex-snapshot
Integrating immunopeptidome analysis for the design and development of cancer vaccines
inferred← citeshttps://doi.org/10.1016/j.tranon.2021.101166openalex-snapshot
The spontaneous remission of cancer: Current insights and therapeutic significance
inferred← citeshttps://doi.org/10.1038/s41392-023-01408-5openalex-snapshot
Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases
inferred← citeshttps://doi.org/10.1038/s41392-025-02343-3openalex-snapshot
Oncolytic viruses: advanced strategies in cancer therapy
inferred← citeshttps://doi.org/10.1038/s41417-020-0189-4openalex-snapshot
Oncolytic virus promotes tumor-reactive infiltrating lymphocytes for adoptive cell therapy
inferred← citeshttps://doi.org/10.1038/s41417-020-0199-2openalex-snapshot
Human SNF5 arming of double-deleted vaccinia virus shows oncolytic and cytostatic activity against central nervous system atypical teratoid/rhabdoid tumor cells
inferred← citeshttps://doi.org/10.1039/d0lc01056aopenalex-snapshot
A microfluidic impedance-based extended infectivity assay: combining retroviral amplification and cytopathic effect monitoring on a single lab-on-a-chip platform
inferred← citeshttps://doi.org/10.1055/a-2618-6935openalex-snapshot
Infecting Cancer to Cure It: The Power of Oncolytic Viruses in Gynecologic Oncology – A Narrative Review
inferred← citeshttps://doi.org/10.1080/08916934.2023.2259126openalex-snapshot
Oncolytic virus oHSV2 combined with PD-1/PD-L1 inhibitors exert antitumor activity by mediating CD4 + T and CD8 + T cell infiltration in the lymphoma tumor microenvironment
inferred← citeshttps://doi.org/10.1080/2162402x.2024.2407532openalex-snapshot
Enhancing T-cell recruitment in renal cell carcinoma with cytokine-armed adenoviruses
inferred← citeshttps://doi.org/10.1089/hum.2020.277openalex-snapshot
Oncolytic Adenovirus ORCA-010 Activates Proinflammatory Myeloid Cells and Facilitates T Cell Recruitment and Activation by PD-1 Blockade in Melanoma
inferred← citeshttps://doi.org/10.1089/hum.2022.206openalex-snapshot
A Recombinant Oncolytic Influenza Virus Carrying GV1001 Triggers an Antitumor Immune Response
inferred← citeshttps://doi.org/10.1089/hum.2022.210openalex-snapshot
Pancreatic Cancer Cell and Gene Biotherapies: Past, Present, and Future
inferred← citeshttps://doi.org/10.1093/immadv/ltad013openalex-snapshot
Combination therapies for the optimisation of Bispecific T-cell Engagers in cancer treatment
inferred← citeshttps://doi.org/10.1111/cas.16105openalex-snapshot
Transient inhibition of neutrophil functions enhances the antitumor effect of intravenously delivered oncolytic vaccinia virus
inferred← citeshttps://doi.org/10.1111/jebm.70116openalex-snapshot
Efficacy and Safety of Oncolytic Viruses Immunotherapy in Advanced Malignancies
inferred← citeshttps://doi.org/10.1126/science.abc4552openalex-snapshot
The microbiome and human cancer
inferred← citeshttps://doi.org/10.1128/jvi.00640-25openalex-snapshot
Efficacy of oncolytic virus in the treatment of intermediate-to-advanced solid tumors: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1134/s000629792306010xopenalex-snapshot
Recombinant Strains of Oncolytic Vaccinia Virus for Cancer Immunotherapy
inferred← citeshttps://doi.org/10.1146/annurev-pathmechdis-032221-115501openalex-snapshot
Innate Immunity and Cancer Pathophysiology
inferred← citeshttps://doi.org/10.1158/0008-5472.can-20-4026openalex-snapshot
Patient-Derived Organoids for Precision Cancer Immunotherapy
inferred← citeshttps://doi.org/10.1158/1078-0432.ccr-23-2174openalex-snapshot
Translational Aspects of Epithelioid Sarcoma: Current Consensus
inferred← citeshttps://doi.org/10.1186/s12645-025-00322-5openalex-snapshot
Nanoparticle-mediated delivery of oncolytic viral genomes: an innovative strategy for tumor-targeted immunotherapy
inferred← citeshttps://doi.org/10.1186/s12935-020-01476-5openalex-snapshot
Synergy between hemagglutinin 2 (HA2) subunit of influenza fusogenic membrane glycoprotein and oncolytic Newcastle disease virus suppressed tumor growth and further enhanced by Immune checkpoint PD-1 blockade
inferred← citeshttps://doi.org/10.1186/s12935-025-04143-9openalex-snapshot
A new strategy for melanoma treatment: an investigation of the clinical value of the combination of immune checkpoint inhibitors and oncolytic viruses
inferred← citeshttps://doi.org/10.1186/s12935-026-04331-1openalex-snapshot
Cracking the shield: oncolytic viruses versus the tumor-immune fortress
inferred← citeshttps://doi.org/10.1186/s12943-026-02651-4openalex-snapshot
Bridging mechanism and clinic: unlocking the full potential of oncolytic virus-based immunotherapy
inferred← citeshttps://doi.org/10.1186/s12964-023-01232-yopenalex-snapshot
Investigating the potential of oncolytic viruses for cancer treatment via MSC delivery
inferred← citeshttps://doi.org/10.1186/s12985-023-02220-xopenalex-snapshot
The efficacy and safety assessment of oncolytic virotherapies in the treatment of advanced melanoma: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1186/s13578-021-00687-1openalex-snapshot
β-adrenergic receptor inhibition enhances oncolytic herpes virus propagation through STAT3 activation in gastric cancer
inferred← citeshttps://doi.org/10.1186/s40164-025-00662-3openalex-snapshot
Next-generation immunotherapeutic approaches for blood cancers: Exploring the efficacy of CAR-T and cancer vaccines
inferred← citeshttps://doi.org/10.1186/s43046-025-00319-6openalex-snapshot
Immune-based cancer therapies: mechanistic insights, clinical progress, and future directions
inferred← citeshttps://doi.org/10.1186/s43556-026-00473-wopenalex-snapshot
Intratumoral microbiota in cancer: molecular mechanism and therapeutic strategies
inferred← citeshttps://doi.org/10.1208/s12249-020-01716-xopenalex-snapshot
Bacteriosomes as a Promising Tool in Biomedical Applications: Immunotherapy and Drug Delivery
inferred← citeshttps://doi.org/10.1371/journal.pone.0285543openalex-snapshot
Preclinical evaluation of oncolytic potential human rotavirus Wt 1-5 in gastric adenocarcinoma
inferred← citeshttps://doi.org/10.20517/2394-4722.2021.212openalex-snapshot
Combining oncolytic virus and radiation therapy for cancer management
inferred← citeshttps://doi.org/10.2147/cpaa.s497836openalex-snapshot
Immunotherapy in Gastrointestinal Cancers: Current Insights
inferred← citeshttps://doi.org/10.2174/0118715206308253240723055019openalex-snapshot
Revolutionizing Cancer Treatment: Unleashing the Power of Combining Oncolytic Viruses with CAR-T Cells
inferred← citeshttps://doi.org/10.2174/1568026623666221107160636openalex-snapshot
Protein Informatics and Vaccine Development: Cancer Case Study
inferred← citeshttps://doi.org/10.2745/dds.38.24openalex-snapshot
Oncolytic virus-induced activation of antitumor immunity and combination with cancer immunotherapy
inferred← citeshttps://doi.org/10.31857/s0320972523060106openalex-snapshot
Recombinant strains of oncolytic vaccinia virus for cancer immunotherapy
inferred← citeshttps://doi.org/10.33263/briac116.1482514852openalex-snapshot
Oncolytic Viruses as Nanomedicines against the Tumor Microenvironment
inferred← citeshttps://doi.org/10.3389/fendo.2025.1517525openalex-snapshot
CAR-T therapy for endocrine neoplasms: novel targets and combination of therapies
inferred← citeshttps://doi.org/10.3389/fimmu.2020.01180openalex-snapshot
Modulation of Inflammation-Induced Tolerance in Cancer
inferred← citeshttps://doi.org/10.3389/fimmu.2022.826164openalex-snapshot
Peptides-Coated Oncolytic Vaccines for Cancer Personalized Medicine
inferred← citeshttps://doi.org/10.3389/fimmu.2022.961796openalex-snapshot
Oncolytic viruses combined with immune checkpoint therapy for colorectal cancer is a promising treatment option
inferred← citeshttps://doi.org/10.3389/fimmu.2022.961805openalex-snapshot
Clinical cancer immunotherapy: Current progress and prospects
inferred← citeshttps://doi.org/10.3389/fimmu.2024.1422031openalex-snapshot
Organoids: new frontiers in tumor immune microenvironment research
inferred← citeshttps://doi.org/10.3389/fimmu.2024.1494887openalex-snapshot
Comparison of differences in immune cells and immune microenvironment among different kinds of oncolytic virus treatments
inferred← citeshttps://doi.org/10.3389/fmmed.2023.1140977openalex-snapshot
Cancer immunotherapies: A hope for the uncurable?
inferred← citeshttps://doi.org/10.3389/fonc.2022.839536openalex-snapshot
Senecavirus A as an Oncolytic Virus: Prospects, Challenges and Development Directions
inferred← citeshttps://doi.org/10.3389/fonc.2022.902190openalex-snapshot
Oncolytic Adenoviral Vector-Mediated Expression of an Anti-PD-L1-scFv Improves Anti-Tumoral Efficacy in a Melanoma Mouse Model
inferred← citeshttps://doi.org/10.3389/fphar.2020.578382openalex-snapshot
Perspectives in Peptide-Based Vaccination Strategies for Syndrome Coronavirus 2 Pandemic
inferred← citeshttps://doi.org/10.3389/fphar.2023.1261575openalex-snapshot
Unleashing the efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma: factors, strategies, and ongoing trials
inferred← citeshttps://doi.org/10.3389/fphar.2026.1751206openalex-snapshot
Progress in the research and development of oncolytic virus therapies
inferred← citeshttps://doi.org/10.3390/bioengineering11030264openalex-snapshot
Applications of Intravital Imaging in Cancer Immunotherapy
inferred← citeshttps://doi.org/10.3390/biology13070521openalex-snapshot
The Role of TRAIL Signaling in Cancer: Searching for New Therapeutic Strategies
inferred← citeshttps://doi.org/10.3390/biomedicines8070204openalex-snapshot
Bi- and Tri-Specific T Cell Engager-Armed Oncolytic Viruses: Next-Generation Cancer Immunotherapy
inferred← citeshttps://doi.org/10.3390/cancers12051295openalex-snapshot
Adenovirus and Immunotherapy: Advancing Cancer Treatment by Combination
inferred← citeshttps://doi.org/10.3390/cancers13040588openalex-snapshot
Oncolytic Virotherapy in Solid Tumors: The Challenges and Achievements
inferred← citeshttps://doi.org/10.3390/cancers14040967openalex-snapshot
Prospect of Prostate Cancer Treatment: Armed CAR-T or Combination Therapy
inferred← citeshttps://doi.org/10.3390/cancers15010321openalex-snapshot
Immunotherapy for Triple-Negative Breast Cancer: Combination Strategies to Improve Outcome
inferred← citeshttps://doi.org/10.3390/cancers17213465openalex-snapshot
The Emerging Role of Oncolytic Virotherapy in Glioblastoma Management
inferred← citeshttps://doi.org/10.3390/cells14221825openalex-snapshot
A Comprehensive Review of Modern Cancer Therapies Utilizing Oncolytic Viruses
inferred← citeshttps://doi.org/10.3390/curroncol28010019openalex-snapshot
Oncolytic Viruses and Hematological Malignancies: A New Class of Immunotherapy Drugs
inferred← citeshttps://doi.org/10.3390/ijms22052517openalex-snapshot
Oncolytic Adenoviruses for Cancer Therapy
inferred← citeshttps://doi.org/10.3390/ijms25073624openalex-snapshot
Immune Cytolytic Activity and Strategies for Therapeutic Treatment
inferred← citeshttps://doi.org/10.3390/jcm11236997openalex-snapshot
Oncolytic Viruses for the Treatment of Bladder Cancer: Advances, Challenges, and Prospects
inferred← citeshttps://doi.org/10.3390/life13081666openalex-snapshot
New Treatment Horizons in Uveal and Cutaneous Melanoma
inferred← citeshttps://doi.org/10.3390/pharmaceutics14091762openalex-snapshot
Immunogenic Cell Death Enhances Immunotherapy of Diffuse Intrinsic Pontine Glioma: From Preclinical to Clinical Studies
inferred← citeshttps://doi.org/10.3390/v14061155openalex-snapshot
Organic Electrochemical Transistors as Versatile Tool for Real-Time and Automatized Viral Cytopathic Effect Evaluation
inferred← citeshttps://doi.org/10.3390/v16071094openalex-snapshot
Clinical Application of Adenovirus (AdV): A Comprehensive Review
inferred← citeshttps://doi.org/10.3390/v17091255openalex-snapshot
Hot and Cold HCC: Uncoupling Viral Oncogenesis and Therapy
inferred← citeshttps://doi.org/10.5772/intechopen.1003010openalex-snapshot
Harnessing the Viral Replication Cycle for Oncolytic Viral and Cancer Immunotherapies Combination Strategies
inferred← citeshttps://doi.org/10.5772/intechopen.1014188openalex-snapshot
Cytotoxicity of Antimicrobial Peptides and Their Assemblies: The Case of Gramicidin D
inferred← citeshttps://doi.org/10.5772/intechopen.95854openalex-snapshot
Advances in Adoptive Cellular Therapy (ACT)
inferred← citeshttps://doi.org/10.6084/m9.figshare.16650017openalex-snapshot
Additional file 1 of β-adrenergic receptor inhibition enhances oncolytic herpes virus propagation through STAT3 activation in gastric cancer
inferred← citeshttps://doi.org/10.6084/m9.figshare.26635146openalex-snapshot
Additional file 1 of The efficacy and safety assessment of oncolytic virotherapies in the treatment of advanced melanoma: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.6084/m9.figshare.26635149openalex-snapshot
Additional file 2 of The efficacy and safety assessment of oncolytic virotherapies in the treatment of advanced melanoma: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.6084/m9.figshare.26635152openalex-snapshot
Additional file 3 of The efficacy and safety assessment of oncolytic virotherapies in the treatment of advanced melanoma: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.71150/jm.2601003openalex-snapshot
Delineated domain of VP2 capsid protein in H-1 parvovirus that determines susceptibility to human cancer cells
inferred← citeshttps://doi.org/10.7554/elife.71156openalex-snapshot
A novel immunopeptidomic-based pipeline for the generation of personalized oncolytic cancer vaccines
inferred← citeshttps://doi.org/10.7759/cureus.40742openalex-snapshot
The Clinical Advances of Oncolytic Viruses in Cancer Immunotherapy
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.